Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114822) titled 'A Phase II Prospective Clinical Study of Bevacizumab in Preventing Radiation-Induced Brain Injury After Stereotactic Radiotherapyfor Lung Cancer Patients with Brain Metastases' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute)
Condition:
Lung cancer patients with brain metastases
Intervention:
Bevacizumab group:Since the initiation of SRT, bevacizumab has been administered at a dosage of 2.5 mg/kg via intravenous drip every two weeks, for a maximum of si...